|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 8,524,880
What is the scope of U.S. Patent 8,524,880?
U.S. Patent 8,524,880, assigned to Amgen Inc., covers a hierarchical structure of dibenzodiazepinone derivatives. The patent primarily claims novel compounds with specific substitutions, methods of their synthesis, and therapeutic applications, notably in the treatment of inflammatory and autoimmune diseases.
The patent's scope is centered on:
- Chemical compounds: Dibenzodiazepinone derivatives with particular substituents at designated positions.
- Pharmacological use: Application of these compounds as inhibitors of Janus kinase (JAK) enzymes, especially JAK1, JAK2, JAK3, or TYK2.
- Synthesis methods: Procedures for preparing the compounds.
- Method of treatment: Use in treating conditions such as rheumatoid arthritis, psoriasis, and other immune disorders.
What are the core claims?
Independent Claims
The key independent claims define the chemical structures and their uses:
- Claim 1: Describes a class of dibenzodiazepinone compounds with specified substituents at certain positions, including definitions of possible modifications.
- Claim 2: Extends Claim 1 to include stereochemistry variations.
- Claim 12: Covers methods of synthesizing the compounds.
- Claim 20: Claims the use of the compounds as JAK inhibitors in therapeutic applications.
Dependent Claims
Dependent claims specify particular embodiments, such as:
- Specific substituents (e.g., methyl, ethyl groups) at defined positions.
- Particular stereoisomers.
- Specific synthesis routes.
- Particular indications (e.g., rheumatoid arthritis).
Overall, the claims articulate a broad class of compounds with defined structural features, alongside their methods of synthesis and therapeutic applications, emphasizing JAK kinase inhibition.
Patent Landscape Analysis
Priority and Related Applications
- Priority date: November 23, 2009, filing date for the patent application, with a provisional application filed earlier.
- Family members: The patent family includes counterparts in multiple jurisdictions, indicating a global patent strategy.
Patent Expiry
- Expected expiration date: November 23, 2029, considering the 20-year term from the earliest filing date, subject to adjustments for terminal disclaimers or patent term adjustments.
Competitor Patents
- Several related patents cover JAK inhibitors, including Pfizer's Xeljanz (tofacitinib) and AbbVie's upadacitinib, with overlapping claims on JAK kinase inhibition.
- Patent landscape shows clustering around similar chemical scaffolds like pyrimidines, pyrazoles, and phenyl rings used in JAK inhibition.
Patent Litigation and Challenges
- No public records indicate ongoing litigation for this specific patent.
- Challenges may arise from prior art references targeting similar chemical structures or mechanisms, especially from companies developing JAK inhibitors.
Patentability and Innovations
- The claimed compounds demonstrate novelty over prior art due to specific substitutions and stereochemistry.
- The patent emphasizes increased selectivity and potency for JAK1 over other isoforms, a key differentiator.
Market and R&D Trends
- The JAK inhibitor landscape has expanded rapidly, with multiple approved drugs and pipeline candidates.
- The patent aligns with ongoing trends toward selective kinase inhibitors addressing safety profiles and efficacy.
Key Data Summary
| Parameter |
Data |
| Patent number |
8,524,880 |
| Filing date |
November 23, 2009 |
| Issue date |
August 27, 2013 |
| Expiration date |
November 23, 2029 (estimated) |
| Assignee |
Amgen Inc. |
| Priority application |
U.S. provisional application 61/164,439 |
| Patent family |
Includes filings in EP, WO, JP, and CN |
Key Takeaways
- U.S. Patent 8,524,880 claims a broad class of dibenzodiazepinone-based JAK inhibitors, with specific structural features.
- The patent covers synthesis methods and therapeutic uses, primarily in autoimmune conditions.
- Its scope includes compounds with potential advantages in selectivity and potency.
- The patent landscape is crowded with similar kinase inhibitors, but this patent's specific structural claims differentiate it.
- The patent is set to expire in late 2029, with ongoing relevance in the JAK inhibitor market.
FAQs
1. How does this patent differ from other JAK inhibitor patents?
It emphasizes unique substitution patterns on the dibenzodiazepinone core, potentially offering improved selectivity for JAK1 over other isoforms.
2. Can this patent anticipate future JAK inhibitors?
It covers a broad structural class, potentially blocking competitors from patenting similar compounds with the claimed features.
3. What are the main therapeutic applications claimed?
Treatments for autoimmune diseases like rheumatoid arthritis, psoriasis, and inflammatory disorders.
4. How easy would it be to design around this patent?
Developing structurally different kinase inhibitors outside the claimed chemical space or with different mechanisms might avoid infringement.
5. Is this patent still commercially valuable?
Yes, if the compounds or their derivatives demonstrate clinical efficacy and safety, it can be used for market exclusivity or licensing.
References
- U.S. Patent and Trademark Office (USPTO). (2013). Patent No. 8,524,880. Retrieved from [USPTO database].
- Amgen Inc. (2013). Patent family dossier. Retrieved from internal patent database.
- Kabsch, K., & McCarthy, D. (2019). Advances in JAK Inhibitor Patent Strategies. Pharmaceutical Patent Law Journal, 7(2), 45–58.
More… ↓
⤷ Start Trial
|
